Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration has approved Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years of age and older. “Dawnzera is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein, a key protein that activates inflammatory mediators associated with acute attacks of HAE,” the company stated. Dawnzera 80mg is self-administered via subcutaneous autoinjector once every four or eight weeks. Dawnzera will be available in the U.S. in the coming days, the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals trading halted, news pending
- Promising Prospects for Ionis Pharmaceuticals: Buy Rating Backed by Olezarsen’s Potential in sHTG Market
- Ionis Pharmaceuticals price target raised to $46 from $45 at UBS
- Positive Outlook for Ionis Pharmaceuticals Driven by Strong Q2 Results and Promising Pipeline Developments
- Ionis Pharmaceuticals Reports Strong Earnings and Growth